About us Contacts Interactions: 118 620
Drug search by name

Nivolumab Intravenous and Hepatic impairment

Result of checking the interaction of drug Nivolumab Intravenous and disease Hepatic impairment for safety when used together.

Check result:
Nivolumab Intravenous <> Hepatic impairment
Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Nivolumab can cause immune-mediated hepatitis. Based on a population pharmacokinetic analysis, no dose adjustment is recommended for patients with mild or moderate hepatic impairment. Caution is recommended when using nivolumab in patients with severe hepatic impairment as this agent has not been studied in these patients. Monitor patients for abnormal liver tests prior to and periodically during treatment. It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for severe or life-threatening transaminase elevations, with or without concomitant elevation in total bilirubin. Administer corticosteroids at a dose of 0.5 to 1 mg/kg/day prednisone equivalents for moderate transaminase elevations. If appropriate modify the dose according to manufacturer recommendations when nivolumab is administered in combination with ipilimumab, and if nivolumab is withheld, ipilimumab should also be withheld. Care should be taken when using nivolumab in patients with liver disease.

Nivolumab Intravenous

Generic Name: nivolumab

Brand Name: Opdivo

Synonyms: Nivolumab

Interaction with food and lifestyle
Drug interactions